West Pharmaceutical Non-GAAP EPS of $2.37 beats by $0.29, revenue of $872.3M beats by $32.32M
Seeking Alpha ·
West Pharmaceutical press release ( WST ): Q2 Non-GAAP EPS of $2.37 beats by $0.29 . Revenue of $872.3M (+13.8% Y/Y) beats by $32.32M . Outlook for Full-Year and Third-Quarter 2026 Full-year 2026 net sales are expected to be in the range of $3.345 billion
AI 시장 분석
West Pharmaceutical Services (WST) reported a Q2 Non-GAAP EPS of $2.37, beating market estimates by $0.29. Revenue also increased by 13.8% year-over-year to $872.3 million, exceeding the consensus by $32.32 million. This strong performance reflects a recovery in overall demand for pharmaceutical packaging and delivery systems, attracting positive investor interest.
상승 영향
- Biotech — With WST's Q2 EPS and revenue both exceeding expectations and guidance being raised, investment sentiment across the pharmaceutical and biotech infrastructure is expected to improve.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 65% · Bearish (Short) 35%
342 participants
Related News
- Tractor Supply lowers guidance amid weak demand for big-ticket items, pet business
- Penske Automotive raises dividend by 1.4% to $1.44
- Vita Coco beats top-line stimates; raises FY26 outlook
- Valley National Bancorp Non-GAAP EPS of $0.30 misses by $0.01, revenue of $560.74M beats by $3.71M
- RTX raises outlook after earnings top estimates on aerospace, defense demand
- Ryder beats top-line and bottom-line estimates; updates FY26 outlook
